NCT05796726 - Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

March 22, 2022

Study Completion Date

March 22, 2022

Conditions

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring METex14 Mutations

Trial Locations (10)

Novartis Investigative Site, Berlin

Novartis Investigative Site, Cologne

Novartis Investigative Site, Düsseldorf

Novartis Investigative Site, Erlangen

Novartis Investigative Site, Essen

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, Giessen

Novartis Investigative Site, München

Novartis Investigative Site, Tübingen

Novartis Investigative Site, Würzburg